<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kyverna Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Kyverna Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kyverna-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358f1478dffbe2df1017a4.webp</url>
<title>Kyverna Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-presents-registrational-trial-primary-analysis-for-miv-cel-in-stiff-person-syndrome-demonstrating-statistically-significant-durable-clinical-benefit-across-all-endpoints-in-an-oral-late-breaker-session-at-aan-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-presents-registrational-trial-primary-analysis-for-miv-cel-in-stiff-person-syndrome-demonstrating-statistically-significant-durable-clinical-benefit-across-all-endpoints-in-an-oral-late-breaker-session-at-aan-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies –</description>
</item>
<item>
<title>Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-presents-longer-term-phase-2-data-for-miv-cel-in-generalized-myasthenia-gravis-at-aan-demonstrating-deep-durable-responses-through-52-weeks</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-presents-longer-term-phase-2-data-for-miv-cel-in-generalized-myasthenia-gravis-at-aan-demonstrating-deep-durable-responses-through-52-weeks</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel’s differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a</description>
</item>
<item>
<title>Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug</description>
</item>
<item>
<title>Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-to-present-new-data-from-neuroimmunology-franchise-at-aan-2026-45</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-to-present-new-data-from-neuroimmunology-franchise-at-aan-2026-45</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated</description>
</item>
<item>
<title>Kyverna Therapeutics to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell</description>
</item>
<item>
<title>Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-appoints-biotech-leaders-sravan-emany-and-andrew-miller-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-appoints-biotech-leaders-sravan-emany-and-andrew-miller-to-board-of-directors</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep</description>
</item>
<item>
<title>Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-appoints-mayo-pujols-130000938</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-appoints-mayo-pujols-130000938</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of miv-celEMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), eff</description>
</item>
<item>
<title>Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-corporate-outlines-130000727</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-corporate-outlines-130000727</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bol</description>
</item>
<item>
<title>Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-present-j-p-130000041</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-present-j-p-130000041</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors s</description>
</item>
<item>
<title>Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-pricing-100-142400328</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-pricing-100-142400328</guid>
<pubDate>Wed, 17 Dec 2025 14:24:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share. The gross proceeds to Kyverna from the offering, before deducting underwriting discounts and commissions and offering exp</description>
</item>
<item>
<title>Kyverna Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-proposed-public-210100421</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-proposed-public-210100421</guid>
<pubDate>Mon, 15 Dec 2025 21:01:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock offered in the public offer</description>
</item>
<item>
<title>Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-positive-topline-113000858</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-positive-topline-113000858</guid>
<pubDate>Mon, 15 Dec 2025 11:30:00 GMT</pubDate>
<description>Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease</description>
</item>
<item>
<title>Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-report-topline-results-193000571</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-report-topline-results-193000571</guid>
<pubDate>Sun, 14 Dec 2025 19:30:00 GMT</pubDate>
<description>– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating</description>
</item>
<item>
<title>Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-business-reports-210500950</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-provides-business-reports-210500950</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data in generalized myasthenia gravis (gMG); on-track to enroll first patient for registrational Phase 3 portion of trial by year-end 2025 Strengthened financial flexibility with up to $150M loan facility to support the continued advancement of the Company’s late-stage indications in gM</description>
</item>
<item>
<title>Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-present-jefferies-london-130000233</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-present-jefferies-london-130000233</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17, 2025 at 1:00 p.m. GMT. A live webcast of the presentation may be accessed via the Investors se</description>
</item>
<item>
<title>Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-secures-150-million-130000518</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-secures-150-million-130000518</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna’s financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS), while also accelerating pre-launch activities Topline data readout of registrational Phase 2 SPS trial now expected in early 2026; narrowed from previous guidance of first half 2026 EMERYVILLE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kyverna Therap</description>
</item>
<item>
<title>Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-positive-interim-103000054</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-announces-positive-interim-103000054</guid>
<pubDate>Wed, 29 Oct 2025 10:30:00 GMT</pubDate>
<description>Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG -- the co-primary endpoints of the Phase 3 trial -- with mean reductions of -8.0 pts and -7.7 points at 24 weeks KYV-101 was well-tolerated with no high-grade CRS and no ICANS observed, further supporting the consistent and manageable safety profile of KYV-101</description>
</item>
<item>
<title>Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-highlights-potential-kyv-150000166</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-highlights-potential-kyv-150000166</guid>
<pubDate>Sat, 25 Oct 2025 15:00:00 GMT</pubDate>
<description>KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with observations from 100 patients treated with KYV-101 to date1 Emerging IIT data in RA reinforce broad potential for KYV-101 in rheumatology indications EMERYVILLE, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clin</description>
</item>
<item>
<title>Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-host-conference-call-120000704</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-host-conference-call-120000704</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, October 29, 2025 at 8:00 AM ET to discuss the interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in generalized myasthenia gravis (gMG). This data will be shared at the American Association of Neuromuscu</description>
</item>
<item>
<title>Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS</title>
<link>https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-highlights-potential-kyv-130500711</link>
<guid isPermaLink="true">https://6ix.com/company/kyverna-therapeutics-inc-common-stock/news/kyverna-therapeutics-highlights-potential-kyv-130500711</guid>
<pubDate>Wed, 24 Sep 2025 13:05:00 GMT</pubDate>
<description>KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011 Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE</description>
</item>
</channel>
</rss>